INSMED INC Shareholders' Equity
INSMED INC (INSM) had Shareholders' Equity of $757.49 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity Attributable to Parent $757.49M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $704.85M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $738.98M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $945.57M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $757.49M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $704.85M 10-Q · filed 2026-08-06 |
| 2025-12-31 | $738.98M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $945.57M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $1.25B 10-Q · filed 2026-08-06 |
| 2025-03-31 | $99.16M 10-Q · filed 2026-08-06 |
| 2024-12-31 | $285.38M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $483.42M 10-Q · filed 2025-10-30 |
| 2024-06-30 | $38.82M 10-Q · filed 2025-10-30 |
| 2024-03-31 | -$464.81M 10-Q · filed 2025-08-07 |
| 2023-12-31 | -$331.92M 10-K · filed 2026-02-19 |
| 2023-09-30 | -$289.36M 10-Q · filed 2024-10-31 |
| 2023-06-30 | -$155.75M 10-Q · filed 2024-10-31 |
| 2023-03-31 | -$44.65M 10-Q · filed 2024-08-08 |
| 2022-12-31 | $87.95M 10-K · filed 2026-02-19 |
| 2022-09-30 | -$29.96M 10-Q · filed 2023-10-26 |
| 2022-06-30 | $44.24M 10-Q · filed 2023-10-26 |
| 2022-03-31 | $119.88M 10-Q · filed 2023-08-03 |
| 2021-12-31 | $410.47M 10-K · filed 2025-02-20 |
| 2021-09-30 | $504.84M 10-Q · filed 2022-10-27 |
| 2021-06-30 | $531.05M 10-Q · filed 2022-10-27 |
| 2021-03-31 | $201.64M 10-Q · filed 2022-08-04 |
| 2020-12-31 | $275.88M 10-K · filed 2024-02-22 |
| 2020-09-30 | $357.06M 10-Q · filed 2021-10-28 |
| 2020-06-30 | $405.32M 10-Q · filed 2021-10-28 |
| 2020-03-31 | $206.70M 10-Q · filed 2021-08-05 |
| 2019-12-31 | $261.67M 10-K · filed 2023-02-23 |
| 2019-09-30 | $304.04M 10-Q · filed 2020-10-29 |
| 2019-06-30 | $356.57M 10-Q · filed 2020-10-29 |
| 2019-03-31 | $144.14M 10-Q · filed 2020-08-06 |
| 2018-12-31 | $208.27M 10-K · filed 2022-02-17 |
| 2018-09-30 | $291.41M 10-Q · filed 2019-10-30 |
| 2018-06-30 | $370.64M 10-Q · filed 2019-10-30 |
| 2018-03-31 | $434.86M 10-Q · filed 2019-08-01 |
| 2017-12-31 | $361.06M 10-K · filed 2021-02-25 |
| 2017-09-30 | $421.31M 10-Q · filed 2017-11-02 |
| 2017-06-30 | $83.44M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $121.68M 10-Q · filed 2017-05-03 |
| 2016-12-31 | $154.48M 10-K · filed 2020-02-25 |
| 2016-09-30 | $217.83M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $250.56M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $282.46M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $311.70M 10-K · filed 2019-02-22 |
| 2015-09-30 | $339.00M 10-Q · filed 2015-11-06 |
| 2015-06-30 | $365.34M 10-Q · filed 2015-08-06 |
| 2015-03-31 | $164.87M 10-Q · filed 2015-05-07 |
| 2014-12-31 | $186.24M 10-K · filed 2018-02-23 |
| 2014-09-30 | $199.27M 10-Q · filed 2014-11-06 |
| 2014-06-30 | $111.55M 10-Q · filed 2014-08-06 |
| 2014-03-31 | $131.74M 10-Q · filed 2014-05-08 |
| 2013-12-31 | $143.32M 10-K · filed 2017-02-23 |
| 2013-09-30 | $157.13M 10-Q · filed 2013-11-05 |
| 2013-06-30 | $105.18M 10-Q · filed 2013-08-06 |
| 2013-03-31 | $107.61M 10-Q · filed 2013-05-07 |
| 2012-12-31 | $120.88M 10-K · filed 2016-02-25 |
| 2012-09-30 | $136.61M 10-Q · filed 2012-11-07 |
| 2012-06-30 | $119.72M 10-Q · filed 2012-08-07 |
| 2012-03-31 | $128.13M 10-Q · filed 2012-05-08 |
| 2011-12-31 | $134.27M 10-K · filed 2015-02-27 |
| 2011-09-30 | $142.34M 10-Q · filed 2011-11-09 |
| 2011-06-30 | $176.74M 10-Q/A · filed 2011-08-08 |
| 2010-12-31 | $192.84M 10-K · filed 2014-03-06 |
| 2009-12-31 | $123.91M 10-K · filed 2013-03-18 |
| 2008-12-31 | -$2.82M 10-K · filed 2012-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |